Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
about
Targeted chemotherapy with nanoparticle albumin-bound paclitaxel (nab-paclitaxel) in metastatic breast cancer: which benefit for which patients?The diagnosis of a metastatic breast tumor from ovarian cancer by the succession of a p53 mutation: a case report.Phase II study of single agent oral vinorelbine as first-line treatment in patients with HER-2 negative metastatic breast cancer.Network pharmacology-based and clinically relevant prediction of the active ingredients and potential targets of Chinese herbs in metastatic breast cancer patients.Recurrent breast cancer: treatment strategies for maintaining and prolonging good quality of life.Self-reported health-related quality of life is an independent predictor of chemotherapy treatment benefit and toxicity in women with advanced breast cancer.Significant survival improvement of patients with recurrent breast cancer in the periods 2001-2008 vs. 1992-2000.Metastatic breast cancer: prolongation of survival in routine care is restricted to hormone-receptor- and Her2-positive tumors.Long-term survival in patients with metastatic breast cancer receiving intensified chemotherapy and stem cell rescue: data from the Italian registry.Ixabepilone (ixempra), a therapeutic option for locally advanced or metastatic breast cancer.Tumor-Specific Systemic Treatment in Advanced Breast Cancer - How Long does it Make Sense?Cost-effectiveness of population screening for BRCA mutations in Ashkenazi jewish women compared with family history-based testingMetastatic breast cancer in a Nigerian tertiary hospital.Extending the duration of first-line chemotherapy in metastatic breast cancer: a perspective review.Defining the survival benchmark for breast cancer patients with systemic relapseNanoparticle albumin-bound paclitaxel (nab-paclitaxel) as second-line chemotherapy in HER2-negative, taxane-pretreated metastatic breast cancer patients: prospective evaluation of activity, safety, and quality of life.Circulating Tumor Cells in Metastatic Breast Cancer: A Prognostic and Predictive Marker.Efficacy of bevacizumab-capecitabine in combination for the first-line treatment of metastatic breast cancer.Effectiveness and cost-effectiveness of sentinel lymph node biopsy compared with axillary node dissection in patients with early-stage breast cancer: a decision model analysis.An 8-gene mRNA expression profile in circulating tumor cells predicts response to aromatase inhibitors in metastatic breast cancer patientsTargeting angiogenesis in metastatic breast cancerAblative Therapies in Metastatic Breast Cancer: A Systematic Review.Taxanes for the treatment of metastatic breast cancer.Clinical outcomes among HR+/HER2- metastatic breast cancer patients with multiple metastatic sites: a chart review study in the US.Topoisomerase II alpha gene amplification is a favorable prognostic factor in patients with HER2-positive metastatic breast cancer treated with trastuzumab.Progression-free survival as a surrogate endpoint in advanced breast cancerNorth central cancer treatment group (NCCTG) N0537: phase II trial of VEGF-trap in patients with metastatic breast cancer previously treated with an anthracycline and/or a taxane.Systemic cancer therapy: achievements and challenges that lie aheadHas first-line therapy had an impact on general outcome in metastatic breast cancer?Willingness of Patients with Breast Cancer in the Adjuvant and Metastatic Setting to Use Electronic Surveys (ePRO) Depends on Sociodemographic Factors, Health-related Quality of Life, Disease Status and Computer SkillsImage-guided intensity-modulated radiotherapy for refractory bilateral breast cancer in a patient with extensive cutaneous metastasis in the chest and abdominal walls.Trade-offs in quality of life and survival with chemotherapy for advanced breast cancer: mature results of a randomized trial comparing single-agent mitoxantrone with combination cyclophosphamide, methotrexate, 5-fluorouracil and prednisoneWhich patients with metastatic breast cancer benefit from subsequent lines of treatment? An update for clinicians.Bevacizumab in the treatment of HER2-negative breast cancer.Rapid Changes in Circulating Tumor DNA in Serially Sampled Plasma During Treatment of Breast Cancer: A Case Report.Eradication of breast cancer cells in patients with distant metastasis: the finishing touches?Critical issues on high-dose chemotherapy with autologous hematopoietic progenitor cell transplantation in breast cancer patients.Predictors of early distant metastasis in women with breast cancer.Treatment strategy for metastatic breast cancer with estrogen receptor-positive tumor.Overall survival (OS) endpoint: an incomplete evaluation of metastatic breast cancer (MBC) treatment outcome.
P2860
Q26745420-9BC0CDDE-298D-4D64-B2AE-5D4991ECA183Q32173659-8D7321BA-638C-4E1D-A89F-8BE92DA39314Q33408664-9A8B7FD3-9301-46E1-8DE7-5A4FCB314A2FQ33688907-8C4AE31D-93F2-4F9D-90B6-18F033380DE9Q33703527-E7CF9EF6-95BE-427E-ABF9-81DE4F796624Q33834401-E67E2B2F-6C0B-4C08-8DC5-6F502D46D873Q33858930-1450C312-EC61-47DE-8740-6CA47FD4B477Q34253243-95E7EABC-39F2-4710-BFDC-728CA4276027Q34366379-57BF495C-F2C5-4F40-9882-DD48AE173CC1Q34611801-7BD8D9FC-7DAE-4D94-98C4-1656D823F839Q34870267-B9B36AB3-6479-4F22-9455-2ABFA981C6C8Q34994574-5AC70C41-6D2A-4768-9AEF-4B44B54AE8F0Q35171957-73BDB56F-E68E-4139-8435-47DA4185B190Q35205290-44F2A9C1-FA4A-4F67-A007-FF37836D6109Q35459288-96C51F63-D1A8-4DDC-BFAF-64A196256692Q35507680-6425B601-296C-41D0-BC88-1D6F592D959EQ35519793-C9683646-EEF2-4C54-AEFA-16BF7CC950D4Q35607779-9E5C925C-19E7-4188-91AA-E47FE79203E1Q35832380-DA6DE4C4-AE5E-49A2-9D93-E2B4D37A79C6Q35927942-13A4A828-4E3F-42B2-8BEB-F344F9E0FC63Q36182795-05FA95D2-BA16-4569-8C53-793AD9305922Q36344204-B6EBA78B-2550-4568-BFE4-AA31F49D19DCQ36364762-BCE56EA0-C96D-45FE-8E49-02F011853612Q36366093-F1D6C23F-CFF0-4A95-9ABC-49B447E45699Q36402262-CC549516-07C3-4434-891C-9568B08B7470Q36552307-619C216C-5AB4-4337-A80B-4A9A91246704Q36652690-C2712129-2C46-4BB1-B215-CC9B727ACD73Q36821958-3B2F99A9-DE2D-4327-BA57-5C591DBCB5EDQ36895808-A0B8E3AE-B53C-419E-B145-BDC8C16CDE2BQ36917641-F05B50DC-7E10-4185-9C73-910D13DABB09Q36944145-CBA9581A-A1B5-47D5-BF2E-7851BBAC675BQ37152795-3040F4DC-EB61-4F8A-8965-51152DF41BD3Q37236305-3C379A32-4EC6-481D-8C94-874F841B2B8EQ37307819-0454386D-8D4E-4430-AA2E-F998589686BEQ37590179-295C4BB2-EA0B-4DC9-960A-6D0D6F05A2B7Q37869838-B094A946-15D9-432A-BA27-54C3BB1733D4Q38040419-14B6CF15-E249-48F9-BCA5-2E80FCA52D0EQ38071245-11045F6B-F5DC-4881-AC49-F9EB5DA38EC5Q38349784-65F3B920-55FB-4800-987B-21775B5C9A57Q38381907-1CE5EC0D-C924-4A46-825D-73700D160724
P2860
Survival of metastatic breast carcinoma patients over a 20-year period: a retrospective analysis based on individual patient data from six consecutive studies.
description
2005 nî lūn-bûn
@nan
2005 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Survival of metastatic breast ...... from six consecutive studies.
@ast
Survival of metastatic breast ...... from six consecutive studies.
@en
type
label
Survival of metastatic breast ...... from six consecutive studies.
@ast
Survival of metastatic breast ...... from six consecutive studies.
@en
prefLabel
Survival of metastatic breast ...... from six consecutive studies.
@ast
Survival of metastatic breast ...... from six consecutive studies.
@en
P50
P356
P1433
P1476
Survival of metastatic breast ...... from six consecutive studies.
@en
P2093
Cinzia Orlandini
Riccardo Rosso
P304
P356
10.1002/CNCR.21359
P407
P577
2005-10-01T00:00:00Z